{
    "clinical_study": {
        "@rank": "110917", 
        "arm_group": [
            {
                "arm_group_label": "Fasted", 
                "arm_group_type": "Other", 
                "description": "Olaparib capsules following no breakfast"
            }, 
            {
                "arm_group_label": "Standard meal", 
                "arm_group_type": "Other", 
                "description": "Olaparib capsules after standard breakfast"
            }, 
            {
                "arm_group_label": "High Fat", 
                "arm_group_type": "Other", 
                "description": "Olaparib capsules after high fat breakfast"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a 2 part study for patients with solid tumours. The purpose of Part A is to measure\n      the amount of olaparib or its breakdown products in the bloodstream for up to 72 hours after\n      eating 3 different breakfasts (high calorie, regular and none). In Part B Patients can take\n      olaparib capsules daily and study assessments will be recorded for 6 months (minimum).\n      Treatment can continue for as long as the patient is benefitting. Throughout the study\n      patients will be monitored for any side effects."
        }, 
        "brief_title": "D081AC00001 Food Interaction With Olaparib Capsule in Patients With Solid Tumours", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Solid Tumours", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients aged \u226518 years, male and female\n\n          -  Able to eat a high-fat breakfast within a 30-minute period, as provided by the study\n             site\n\n          -  Histologically or, where appropriate, cytologically confirmed malignant solid tumour\n             refractory or resistant to standard therapy and for which no suitable effective\n             standard therapy exists\n\n          -  ECOG performance status \u22642\n\n          -  Normal organ and bone marrow function measured within 28 days prior to administration\n             of IP as defined in protocol\n\n        Exclusion Criteria:\n\n          -  Participation in another clinical study with an IP  during the last 14 days (or a\n             longer period depending on the defined characteristics of the agents used)\n\n          -  Patients receiving any systemic chemotherapy or radiotherapy (except for palliative\n             reasons) within 2 weeks prior to study treatment (or a longer period depending on the\n             defined characteristics of the agents used).\n\n          -  Toxicities (\u2265CTCAE Grade 2) caused by previous cancer therapy, excluding alopecia\n\n          -  Patients unable to fast for up to 14 hours or who have type I or type II diabetes\n\n          -  Patients who have gastric, gastro-oesophageal or oesophageal cancer"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "35", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01851265", 
            "org_study_id": "D081AC00001", 
            "secondary_id": "2013-001255-13"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Fasted", 
                    "Standard meal", 
                    "High Fat"
                ], 
                "description": "400mg olaparib capsule formulation taken 30 minutes after allocated meal. 5-14 days between arms.", 
                "intervention_name": "Olaparib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Fasted", 
                "description": "Allocated breakfast prior to dosing with 400mg olaparib capsules", 
                "intervention_name": "Dietary Fasted", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Standard meal", 
                "description": "Allocated breakfast prior to dosing with 400mg olaparib capsules", 
                "intervention_name": "Dietary standard", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "High Fat", 
                "description": "Allocated breakfast prior to dosing with 400mg olaparib capsules", 
                "intervention_name": "Dietary High Fat", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "oncology, cancer, tumour, neoplasm, anticancer drug, food effect, area under the curve, pharmacokinetics, olaparib, solid tumour, metabolites, drug availability", 
        "lastchanged_date": "May 26, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Edegem", 
                        "country": "Belgium"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leuven", 
                        "country": "Belgium"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wilrijk", 
                        "country": "Belgium"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Maastricht", 
                        "country": "Netherlands"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Glasgow", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Manchester", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Research Site"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "Netherlands", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Two-part, Randomised, Open-label, Multicentre, Phase I Study to Determine the Effect of Food on the Pharmacokinetics of Olaparib Following Single 400 mg Doses of the Capsule Formulation in Patients With Advanced Solid Tumours", 
        "overall_official": [
            {
                "affiliation": "AstraZeneca Senior Research Physician", 
                "last_name": "Anitra Fielding", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "UZ Antwerpen", 
                "last_name": "Christian Rolfo", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "AstraZeneca Study Statistician", 
                "last_name": "Wendy Bannister", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Belgium: Federal Agency for Medicinal Products and Health Products", 
                "Belgium: Institutional Review Board", 
                "Netherlands: Medical Ethics Review Committee (METC)", 
                "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
                "United Kingdom: Research Ethics Committee", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Rate and extent of absorption of olaparib following single-dose olaparib by assessment of maximum plasma olaparib concentration (Cmax) and time to reach maximum plasma concentration (tmax)", 
                "measure": "Pharmacokinetics of Olaparib (Cmax and tmax)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples will be collected in each of the 3 treatment periods in Part A at these time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, and 72hours post dose"
            }, 
            {
                "description": "Rate and extent of absorption of olaparib following single-dose olaparib by assessment of area under the plasma concentration time curve from zero to the last measurable time point (AUC0-t)", 
                "measure": "Pharmacokinetics of Olaparib (AUC0-t)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples will be collected in each of the 3 treatment periods in Part A at these time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, and 72hours post dose."
            }, 
            {
                "description": "Rate and extent of absorption of olaparib following single-dose olaparib by assessment of area under the plasma concentration time curve from zero to infinity (AUC)", 
                "measure": "Pharmacokinetics of Olaparib (AUC)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples will be collected in each of the 3 treatment periods in Part A at these time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, and 72hours post dose"
            }, 
            {
                "description": "Rate and extent of absorption of olaparib following single-dose olaparib by assessment of apparent clearance following oral administration (CL/F), apparent volume of distribution (Vz/F), terminal rate constant (\u03bbz), and terminal half-life (t\u00bd)", 
                "measure": "Pharmacokinetics of Olaparib Pharmacokinetics of Olaparib (CL/F, Vz/F, \u03bbz and t\u00bd)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples will be collected in each of the 3 treatment periods in Part A at these time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, and 72hours post dose."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01851265"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Assessment of adverse events (AEs), graded by CTCAE (v4.0), physical examination, vital signs (including BP and pulse), standard 12-lead ECG and evaluation of laboratory parameters (clinical chemistry, haematology, and urinalysis). Assessment of physical examination, vital signs, ECG and evaluation of laboratory parameters will occur at screening, on the day before dosing in each treatment period and 30 days after last dose.", 
            "measure": "Safety monitoring of Olaparib", 
            "safety_issue": "Yes", 
            "time_frame": "AEs will be collected from signed informed consent up to 30-day post last dose in Part A. For patients  in Part B, AE's will be collected until the final patient has completed 6 months in Part B, including 30 day follow up for those who discontinue"
        }, 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor)", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}